贝达药业：BPI-572270胶囊获得临床试验批准通知书

Core Viewpoint - Beida Pharmaceutical's subsidiary, Hangzhou Jingyao Biotechnology, has received approval from the National Medical Products Administration (NMPA) for clinical trials of BPI-572270 capsules aimed at treating patients with advanced malignant solid tumors [1][2]. Group 1 - BPI-572270 is a novel compound developed by the company, possessing complete intellectual property rights, and is classified as a new type of potent pan-RAS non-degradable molecular glue inhibitor [2]. - The mechanism of action involves inducing the chaperone protein Cyclophilin A (CYPA) to bind to activated RAS mutant proteins, causing conformational changes that prevent RAS from interacting with downstream signaling proteins, thereby blocking MAPK signaling pathways responsible for tumor growth [2]. - Preclinical studies indicate that BPI-572270 exhibits strong inhibitory effects on various tumor cells harboring RAS mutations (including KRAS, NRAS, HRAS) across multiple cancer types such as pancreatic cancer, non-small cell lung cancer, and colorectal cancer, while also demonstrating excellent pharmacokinetic properties and good safety [2]. Group 2 - The drug has the potential to treat multiple RAS-mutant cancers as a monotherapy or in combination with other treatments for more comprehensive disease control [2].